Search Results
Aug 28, 2026, 08:03 ET Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
www.formosapharma.com.About EirGenix, Inc.EirGenix Inc. (TWSE: 6589) operates on a dual business model combining CDMO with Product Development to fully leverage its cGMP manufacturing facilities and highly qualified technical staff. The company's core competitiveness
More news about: Formosa Pharmaceuticals Inc.,
Aug 28, 2026, 06:03 ET Tigermed Announces 2026 Interim Results
laboratory services team exceeded 1,800 people, with 25 facilities across China, the U.S., and Europe.Furthermore, in H1 2026, the 4,300 sqm CDMO GMP manufacturing facility in Exton, U.S. commenced operations. As of June 30, 2026, Tigermed had 3,094 ongoing Site Management projects, up 25% year-over-year.
More news about: Hangzhou Tigermed Consulting Co., Ltd.
Aug 28, 2026, 05:56 ET Tigermed Announces 2026 Interim Results
laboratory services team exceeded 1,800 people, with 25 facilities across China, the U.S., and Europe.Furthermore, in H1 2026, the 4,300 sqm CDMO GMP manufacturing facility in Exton, U.S. commenced operations. As of June 30, 2026, Tigermed had 3,094 ongoing Site Management projects, up 25% year-over-year.
More news about: Hangzhou Tigermed Consulting Co., Ltd.
Aug 28, 2026, 03:00 ET Evonik baut Produktionskapazitäten für lipidbasierte Wirkstoffe in Vancouver aus
Laboratories, ehemals Transferra Nanosciences und Northern Lipids, ist seit den 1990er Jahren ein Pionier in der lipidbasierten Wirkstoffabgabe und bietet heute CDMO-Dienstleistungen für fortschrittliche LNP- und liposomale Abgabesysteme – von der Formulierungsforschung bis zur GMP-Produktion für klinische Studien
More news about: Evonik Industries AG
Aug 28, 2026, 03:00 ET Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
Laboratories, formerly Transferra Nanosciences and Northern Lipids, has been a pioneer in lipid-based drug delivery since the 1990s and today provides CDMO services for advanced LNP and liposomal delivery systems, from formulation research through GMP clinical trial manufacturing and commercial process
More news about: Evonik Industries AG
Aug 28, 2026, 03:00 ET Evonik abre una nueva planta de fabricación con certificación GMP en Vancouver
Northern Lipids, ha sido pionera en la administración de fármacos basada en lípidos desde la década de 1990 y, en la actualidad, ofrece servicios de CDMO para sistemas avanzados de administración de LNP y liposomales, desde la investigación de formulación hasta la fabricación para ensayos clínicos bajo
More news about: Evonik Industries AG
Aug 27, 2026, 18:58 ET Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
8 online sequentially, boosting its global manufacturing capacity to 1,385,000 liters by 2032."Building on our position as a global top-tier CDMO, this capital raise sets the stage for our next phase of growth," said John Rim, President and CEO of Samsung Biologics. "We are confident that executing
More news about: Samsung Biologics
Aug 27, 2026, 15:17 ET Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
Laboratories, formerly Transferra Nanosciences and Northern Lipids, has been a pioneer in lipid-based drug delivery since the 1990s and today provides CDMO services for advanced LNP and liposomal delivery systems, from formulation research through GMP clinical trial manufacturing and commercial process
More news about: Evonik Industries AG
Aug 27, 2026, 09:00 ET Rose BioSolutions Appoints Thomas VanCott, Ph.D., as Head of HemaCare
helping life sciences organizations develop and manufacture advanced therapies for patients. Most recently, he served as CEO of Excellos, a cell therapy CDMO supporting customers from starting materials through commercial cGMP manufacturing.In this role, he will oversee Rose Bio's HemaCare business
More news about: Rose BioSolutions
Aug 26, 2026, 23:09 ET Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
boost drug design efficiency and accelerate practical applications.CDMO Commercial Manufacturing Fuels Revenue Growth; CMC Segment Successfully Achieves ProfitabilityDuring the Reporting Period, two new CDMO commercialization projects were successfully landed. Through structural adjustment
More news about: Viva Biotech
Aug 26, 2026, 10:57 ET Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
boost drug design efficiency and accelerate practical applications.CDMO Commercial Manufacturing Fuels Revenue Growth; CMC Segment Successfully Achieves ProfitabilityDuring the Reporting Period, two new CDMO commercialization projects were successfully landed. Through structural adjustment
More news about: Viva Biotech
Aug 26, 2026, 02:15 ET 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), today announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade
More news about: Genezen
Aug 25, 2026, 11:12 ET Cambrex High Point achève les inspections préalables à l'autorisation menées par la FDA, la PMDA et la TGA, renforçant ainsi ses capacités de production commerciale
25 août 2026 /PRNewswire/ -- Cambrex, l'un des principaux acteurs mondiaux du secteur du développement et de la fabrication sous contrat (CDMO), a annoncé aujourd'hui avoir achevé avec succès trois inspections préalables à l'autorisation (PAI) menées sur son site de High Point, en Caroline du
More news about: Cambrex
Aug 25, 2026, 10:15 ET Peptide Synthesis Market worth $1.54 billion by 2031 - Exclusive Report by MarketsandMarkets™
transactions include Samsung Biologics Co., Ltd.'s (South Korea) proposed acquisition of PolyPeptide Group AG (Switzerland) to enter the global peptide CDMO market and CordenPharma International GmbH's (Switzerland) acquisition of AmbioPharm, Inc. (US) to strengthen complex peptide capabilities and expand
More news about: MarketsandMarkets
Aug 25, 2026, 08:45 ET WuXi Biologics Reports Strong Profitable Growth in H1 2026
please visit: www.wuxibiologics.com*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing
More news about: WuXi Biologics
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
houses 60,000 liters of antibody capacity and ADC commercial lines; Hangzhou site has 80,000 liters of antibody capacity, supporting global supply and CDMO services.Sustainable Development and ESG Commitment9,000 employees worldwide, with global R&D centers
More news about: Innovent Biologics
Aug 25, 2026, 06:00 ET Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
N.J., Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and
More news about: Cambrex
Aug 25, 2026, 06:00 ET Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
N.J., Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and
More news about: Cambrex
Aug 25, 2026, 06:00 ET Cambrex High Point schließt die Inspektionen im Vorfeld der Zulassung durch die FDA, die PMDA und die TGA ab und baut damit seine Kapazitäten für die kommerzielle Produktion weiter aus
25. August 2026 /PRNewswire/ -- Cambrex, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO), gab heute den erfolgreichen Abschluss von drei Inspektionen vor der Zulassung (Pre-Approval Inspections, PAIs) in seinem Werk in High Point, North
More news about: Cambrex
Aug 25, 2026, 06:00 ET A Cambrex High Point concluiu as inspeções de pré-aprovação da FDA, PMDA e TGA, fortalecendo sua capacidade de fabricação em escala comercial
25 de agosto de 2026 /PRNewswire/ -- A Cambrex, uma organização líder em desenvolvimento e fabricação por contrato (CDMO), anunciou hoje a conclusão bem-sucedida de três inspeções de pré-aprovação (PAIs) em sua unidade de High Point, na Carolina do Norte, realizadas pela
More news about: Cambrex
Aug 25, 2026, 06:00 ET Cambrex High Point completa las inspecciones previas a la autorización de la FDA, la PMDA y la TGA, lo que impulsa sus capacidades de fabricación comercial
25 de agosto de 2026 /PRNewswire/ -- Cambrex, una organización líder mundial de desarrollo y fabricación por contrato (CDMO), ha anunciado hoy la finalización con éxito de tres inspecciones previas a la autorización (PAI) en sus instalaciones de High
More news about: Cambrex
Aug 25, 2026, 06:00 ET Cambrex High Point completa las inspecciones previas a la aprobación de la FDA, la PMDA y la TGA
25 de agosto de 2026 /PRNewswire/ -- Cambrex, organización líder mundial en desarrollo y fabricación por contrato (CDMO), anunció hoy la finalización exitosa de tres inspecciones previas a la aprobación (PAI) en su planta de High Point, Carolina del Norte, por parte de
More news about: Cambrex
Aug 25, 2026, 06:00 ET 캠브렉스 하이 포인트, FDA•PMDA•TGA 사전 승인 심사 완료... 상업 생산 역량 강화
이스트러더퍼드, 뉴저지, 2026년 8월 25일 /PRNewswire/ -- 세계적인 위탁개발생산기업(Contract Development and Manufacturing Organization, CDMO) 캠브렉스(Cambrex)가 8월 25일, 노스캐롤라이나주 하이 포인트(High Point) 시설에서 미국 식품의약청(FDA), 일본 의약품의료기기종합기구(PMDA), 오스트레일리아 치료제품관리청(TGA)의 사전 승인 심사(Pre-Approval Inspections,
More news about: Cambrex
Aug 24, 2026, 08:35 ET WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
XPLM2 in Jiangyin site secures vertical integration into the critical payload and linker supply chain.The Group was named the winner of "Best CDMO" for 3 consecutive year from 2023 to 2025, as well as "Best CRO" at the 2025 World ADC Awards.The Group is committed to ESG excellence, reflected
More news about: WuXi XDC
Aug 24, 2026, 07:00 ET Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
signed customer purchase orders for specified CDMO services under existing contractual arrangements, whether or not such amounts have been invoiced. Management uses committed customer orders as an indicator of committed commercial activity and anticipated CDMO utilization, and we believe this measure provides
More news about: Scinai Immunotherapeutics Ltd.